Several studies have indicated that the genetic diversity of human T-cell leukemia virus type 1 (HTLV-1), a virus associated with adult T-cell leukemia, is significantly lower than that of other retroviruses, including that of human immunodeficiency virus type 1 (HIV-1). To test whether HTLV-1 variation is lower than other retroviruses, a tractable vector system has been developed to measure reverse transcription accuracy in one round of HTLV-1 replication. This system consists of a HTLV-1 vector that contains a cassette with the neomycin phosphotransferase (neo) gene, a bacterial origin of DNA replication, and the lacZ␣ peptide gene region (the mutational target). The vector was replicated by trans-complementation with helper plasmids. The in vivo mutation rate for HTLV-1 was determined to be 7 ؋ 10 ؊6 mutations per target base pair per replication cycle. The majority of the mutations identified were base substitution mutations, namely, G-to-A and C-to-T transitions, frameshift mutations, and deletion mutations. Mutation of the methionine residue in the conserved YMDD motif of the HTLV-1 reverse transcriptase to either alanine or valine (i.e., M188A or M188V) led to a factor of two increase in the rate of mutation, indicating the role of this motif in enzyme accuracy. The HTLV-1 in vivo mutation rate is comparable to that of bovine leukemia virus (BLV), another member of the HTLV/BLV genus of retroviruses, and is about fourfold lower than that of HIV-1. These observations indicate that while the mutation rate of HTLV-1 is significantly lower than HIV-1, this lower rate alone would not explain the low diversity in HTLV-1 isolates, supporting the hypothesis that HTLV-1 replicates primarily as a provirus during cellular DNA replication rather than as a virus via reverse transcription.
Human T-cell leukemia virus type 1 (HTLV-1) is a member of the human T-cell leukemia virus/bovine leukemia virus (HTLV/BLV) genus of the Retroviridae family. HTLV-1 has been shown by epidemiology to be associated with adult T-cell leukemia, HTLV-1-associated myelopathy-tropical spastic paraparesis, and polymyositis (5) . Infection of HTLV-1 is endemic in Melanesia, Japan, the Caribbean, and sub-Saharan Africa. There is a remarkable amount of homogeneity among HTLV-1 isolates (12, 13, 15, 25, 35, 41, (43) (44) (45) 52) . For example, isolates from Japan have close to 99% homology, and isolates from Japan, the Caribbean, and Africa can also share as much as 99% homology. It has been suggested that HTLV-1 isolates endemic in different races may be of utility in studying the movement of ancient human populations or in anthropologic studies (12) . HTLV-1 isolates from Melanesia would not be as useful, since there is not as much sequence homology to the original Japanese isolate (11) . This suggests that HTLV-1 may have originated in the Pacific Rim rather than in Africa. Genetic diversity among isolates of HTLV-2 is equally low (48) .
The low level of genetic diversity in HTLV-1 has been speculated to be due to oligoclonal expansion of infected cells and very low levels of virus replication in infected individuals (6, 7, 54) . The low levels of virus replication observed in cell culture has been used to support this hypothesis. Replication of the viral genome primarily as a provirus during cellular DNA replication would provide a higher-fidelity mode of virus replication than viral nucleic acid replication via reverse transcription.
An advantage for the virus in doing this is that HTLV may be able to escape immune selection. It has been shown that the HTLV envelope protein becomes nonfunctional with a limited number of mutations, which is in contrast to the human immunodeficiency virus type 1 (HIV-1) envelope (38) .
To help dissect the basis of genetic variation of retroviruses, the mutation rate per replication cycle has been studied extensively. This work was initiated by designing systems to determine the mutation rate per base pair per replication cycle for spleen necrosis virus (SNV), an avian C-type retrovirus similar to the murine type C retroviruses, using an amber codon reversion assay with an SNV vector (9, 10) . A similar reversion assay was used to determine the mutation rate of murine leukemia virus (MLV) (53) . The in vivo forward mutation rates for various types of mutations were calculated with the lacZ␣ peptide gene as a reporter gene for mutations and the bluewhite colony color selection method for identifying mutant proviruses in Escherichia coli (36, 37) . The major types of mutations found were base-pair substitutions, frameshifts, simple deletions, and deletions with insertions. The overall in vivo mutation rate of SNV in this system was determined to be 10 Ϫ5 mutations/target base pair/replication cycle.
These studies have been extended to BLV (32) . BLV was found to have a mutation rate of 4 ϫ 10
Ϫ6
, which is 2.5 times less than that for SNV. A similar distribution of mutation types was found with BLV relative to that of SNV, indicating that a common property of reverse transcriptase (RT) is responsible for all of these error processes. Temin speculated that this common property was the strand-transfer process (50) . The mutation rate of HIV-1 was determined with a vector containing the lacZ␣ peptide gene (26, 31) . The mutation rate of HIV-1 in this system was determined to be 3 ϫ 10 Ϫ5 mutations per target base pair per cycle. The Vpr protein of HIV-1 influences the mutation rate and involves the interaction of Vpr with the cellular DNA repair enzyme uracil DNA glycosylase (27, 30) .
Phylogenetic analysis of RTs has indicated several conserved domains and structures that are important for RT function (34) . For example, the fingers, palm, and thumb subdomains of the HIV-1 RT catalytic domain are thought to be well conserved among other RTs because of the importance of this region of the enzyme for contacting the primer-template, and binding the incoming deoxynucleoside triphosphate (20) . The conserved YXDD motif is important because it has been associated with resistance to nucleoside analogs, decreases in enzymatic activity and viral infectivity, and changes in the positioning of the primer in the template-primer complex (39) .
The objectives of this study were to determine the accuracy of HTLV-1 reverse transcription and to see if amino acid substitutions in the conserved YMDD motif of HTLV-1 RT would influence the rate of HTLV-1 mutation. To do this, a tractable genetic system was developed to measure the forward rate of mutation using the lacZ␣ peptide gene as a reporter for mutations. The mutation rate of HTLV-1 was determined to be 7 ϫ 10 Ϫ6 mutations/target base pair/replication cycle. This rate is comparable to that of BLV, but is about fourfold lower than the mutation rate of HIV-1. Mutation of the YMDD motif doubled the mutation rate of HTLV-1.
MATERIALS AND METHODS
HTLV-1 vector construction. The HTLV-1 shuttle vector pH1sh (Fig. 1) was constructed from pHTLV-CMVNEO (kindly provided by David Derse, National Cancer Institute) (8) in a two-step process. First, a deletion of the pol region was done by deletion of a HindIII fragment. Second, a cassette containing the simian virus 40 (SV40) promoter driving expression of the neomycin phosphotransferase (neo) gene, a bacterial origin of DNA replication, and the lacZ␣ peptide gene region from a previously described HIV-1 vector (31) was inserted in place of the CMVNEO cassette to create pH1sh. The plasmid pCMV-HT1 (kindly provided by David Derse) was used as a helper plasmid to trans-complement the HTLV-1 shuttle vector with gag, pol, tax, and rex (8) . The plasmid pSV-A-MLV-env was also used as a helper plasmid and has been previously described (24) . The HTLV-1 RT variants M188A and M188V were made in pCMV-HT1 by a primary-combinatorial two-step PCR protocol (17) .
Transfections, infections, and cocultivations. The CEM-A cell line used was obtained from the NIH AIDS Reagent Program and was maintained in RPMI 1640 supplemented with 2 mM L-glutamine containing 10% calf serum. The HTLV-1 vector and expression plasmids were transfected into CEM-A cells by use of either dimethyl sulfoxide-Polybrene (18) or Superfect (Qiagen). CEM-A cells were infected in the presence of Polybrene (28) . Cocultivation of CEM-A target cells with virus-producing cells was also done as previously described (29, 32) . Briefly, virus-producing cells (typically, 2.5 ϫ 10 5 cells per 60-mm petri dish or 5 ϫ 10 5 cells per 100-mm petri dish or 7.5 ϫ 10 5 cells per 150-mm petri dish were treated with mitomycin C (8 g/ml), an inhibitor of host cell DNA synthesis, for 1.5 h at 37°C. The cells were then washed three times with fresh medium, and CEM-A target cells equivalent to the number of treated virus-producing cells were added. Two days after cocultivation, selective medium containing G418 was added. Control experiments were done with each cocultivation experiment to ensure that mitomycin C-treated, virus-producing cells did not proliferate and no longer adhered to the surfaces of culture dishes. Cells expressing the neo gene were selected with the neomycin phosphotransferase analog, G418, until the formation of colonies (typically about 3 weeks).
Analysis of HTLV-1 reverse transcription accuracy in a single replication cycle. The experimental protocol developed to assay a single cycle of HTLV-1 vector replication is shown in Fig. 1 . The protocol contains three steps. In step 1, the HTLV-1 vector was introduced into CEM-A cells by transfection and placed under G418 selection. Cell clones were then transiently transfected with the helper plasmids. In step 2, vector virus was harvested 48 h posttransfection from step 1 cells and used to infect fresh CEM-A cells. G418-resistant cell clones were transiently transfected with the helper plasmids (step 2 cells).
Step 2 clones were tested by Southern analysis to ensure that only a single vector proviral DNA was present. The lacZ␣ peptide gene in the vector proviral DNA of step 2 clones was sequenced to confirm that no mutations were introduced. In step 3, vector virus was transferred to fresh CEM-A target cells by cocultivation for 24 to 48 h after transient transfection of helper plasmids; cells were then placed under G418 selection (step 3 cells). Cocultivation was used to produce step 3 cells to maximize the number of step 3 cells for analysis of the mutant frequency.
Recovery of shuttle vector proviral DNA and DNA sequencing of the lacZ␣ peptide region. Purified genomic DNA (42) digested with the restriction enzyme SalI to release the neo, pACYC origin of replication, and lacZ␣ peptide gene sequences from the HTLV-1 shuttle vector proviral DNA (Fig. 1 ). Proviral DNA was purified with the Lac repressor protein as previously described (32) . The Lac repressor protein was purified from E. coli HB101/lac pIQ (kindly supplied from Tom Record, University of WisconsinMadison) as previously described (23) . The purified proviral DNA was ligated and used to electroporate competent E. coli XL1 Blue cells (Stratagene). Kanamycin-resistant bacterial colonies were selected in the presence of the isopropyl-␤-D-thiogalactoside (IPTG) inducer. The ratio of white plus light-blue bacterial colonies to total bacterial colonies observed provided a forward mutant frequency for a single retroviral replication cycle. Plasmid DNA was purified (42) and sequenced in the lacZ␣ peptide gene region in order to determine the mutation rate.
RESULTS
A HTLV-1 single cycle replication assay for mutation detection. In order to measure HTLV-1 reverse transcription accuracy, a replication assay was developed to measure the in vivo mutation rate in a single cycle of replication. An HTLV-1 shuttle vector was constructed in order to identify mutations that had occurred during HTLV-1 replication. The vector contained a cassette which included the neo gene under control of the SV40 promoter, a bacterial origin of plasmid DNA replication, and the lacZ␣ peptide gene region as a mutational target. This cassette has been previously used for analysis of reverse transcription accuracy of HIV-1 and BLV (31, 32) . This vector, pH1sh, can replicate in both mammalian cells as a virus and in bacterial cells as a plasmid.
The assay developed is shown in Fig. 1 . CEM-A cells were used in these studies because they are adherent T-lymphoid cells that are permissive for HTLV-1 replication (51). The utility of adherent cells is that they could be placed under drug selection when vector virus was introduced either by transfection or infection and form drug-resistant colonies. The HTLV-1 shuttle vector, pH1sh, was first introduced into fresh CEM-A cells by transfection and placed under G418 selection (step 1 cells). G418-resistant colonies were pooled and then transfected with helper plasmids. The supernatant from these cells was used to infect fresh CEM-A cells. Titers of the vector virus were very low (ϳ10 CFU/ml) but generated several infected cell clones for further studies. Prior to use in the single cycle replication assay, a few selected clones were analyzed for the presence of a single integrated provirus. Data indicated that the selected clones contained single integrated copies of the HTLV-1 vector (data not shown). Transfection of helper plasmids into these cells (step 2 cells) was done to allow for virus production of the vector. These virus-producing cells were treated with mitomycin C and cocultured with fresh CEM-A cells. Cocultivation was used to produce step 3 cells to maximize the number of step 3 cells for analysis of the mutant frequency. Following cocultivation, cells were placed under G418 selection. Approximately 1,000 to 1,800 G418-resistant colonies were obtained per 7.5 ϫ 10 5 target cells cocultivated with step 2 cells. The G418 resistant cells (step 3 cells) were then pooled from over 40,000 colonies, and the total DNA was purified. The purified DNA was digested with SalI, and the cassette containing the lacZ␣ peptide gene region mutational target containing the Lac operator sequence was purified using the Lac repressor protein.
Mutant frequency, type, and location in HTLV-1 replicated with wild-type RT. The mutant frequency from several parallel experiments indicated that the average mutant frequency was 0.0009 (33/36,561) mutation per target base pair per replication cycle (Table 1) . Nucleotide sequence analysis of the lacZ␣ peptide gene region was done to determine the types of mutations responsible for the mutant colony color phenotype (Table 2). Of the 33 mutants recovered, 20 (61%) had base substitution mutations. Of the 20, 14 (70%) were G-to-A and C-to-T transition mutations. One C-to-T hypermutant was identified, which contained two C-to-T transition mutations 
VOL. 74, 2000 HTLV-1 REVERSE TRANSCRIPTION ACCURACYwithin the mutational target. Of the 33 mutants, 7 (21%) had frameshift mutations. Six of the seven frameshift mutations were ϩ1 frameshifts in runs of A's, C's, or T's. Finally, 6 of the 33 mutants (18%) had deletion mutations. The deletion mutations were either simple deletions (four of six) that contained base pair homology at the deletion junctions or were more complex deletions with insertion mutations (inserted sequences of unknown origin). Analysis of the location of mutations indicated that the base substitutions and frameshift mutations occurred at locations in the lacZ␣ peptide gene region where substitutions and frameshift mutations had been previously characterized for both BLV and HIV-1 (Fig. 2) . This suggests that there are mutational hotspots within the lacZ␣ peptide gene region that are recognized as such by many RTs. The deletion mutations were located throughout the lacZ␣ peptide gene region but in most instances had deletion junctions near locations that may be mutational hotspots. The deletion junctions for the simple deletions had either 3-or 4-bp homology (Fig. 3) . Two deletions with insertion mutants were identified that did not have base pair homology at the deletion junctions.
Mutant frequency and characterization of HTLV-1 replicated with RT variants in one round of replication. To determine whether amino acid substitutions in the HTLV-1 RT could influence the accuracy of the reverse transcription process, the methionine residue at position 188 was changed to either alanine (M188A) or valine (M188V). M188 lies in the highly conserved YXDD motif. The HTLV-1 vector was then replicated in parallel with RT containing either the M188A mutation or the M188V mutation or with wild-type RT. Following recovery of proviruses from infected CEM-A target cells, the mutant frequency observed after replication with the M188A RT was found to be 0.0023 (18/7,916 ) mutant/cycle (Table 1 ). This is significantly higher ( 2 ϭ 11; P Ͻ 0.005) than the mutant frequency found by replication with wild-type HTLV-1 RT (33/36,561) ( Table 1 ). The mutant frequency observed following replication with M188V RT was 0.0021 (20/ 9,741) mutant/cycle ( Table 1 ). The mutant frequency for M188V is also significantly higher ( 2 ϭ 9; P Ͻ 0.005) than the mutant frequency obtained after replication with wild-type HTLV-1.
To determine whether the types of mutations that occurred when the HTLV-1 vector was replicated with either M188A or M188V were different than when the vector was replicated with wild-type RT, the 38 mutants isolated were sequenced. Table 2 summarizes the types of mutants identified. A total of 39 and 35% of the mutations identified for both M188A and M188V were substitution mutations (7 of 18 and 7 of 20), respectively. For both M188A and M188V, G-to-A and C-to-T transition mutations were the most common substitutions, occurring either 71% (5 of 7) or 86% (6 of 7) of the time, respectively. Frameshift mutations were observed for both M188A and M188V and represented 44% (8 of 18) or 45% (9 of 20) of the total mutants, respectively. This trend indicates a doubling of frameshift mutations compared to that with wildtype HTLV-1 RT (i.e., 7 of 33, 21%) ( Table 2 ). M188A and M188V led to deletion mutations either 11% (2 of 18) or 15% (3 of 20) of the total, respectively. The deletion mutations included both simple deletions and deletions with insertions. A G-to-A hypermutant was recovered with M188A that had two G-to-A mutations, and a C-to-T hypermutant was recovered with M188V that had two C-to-T mutations in the lacZ␣ peptide gene region.
The locations of the base substitution and frameshift mutations were compared to that observed with wild-type RT (Fig.  2) . In general, the locations of mutations identified when HTLV-1 was replicated with either M188A or M188V were similar to that seen with wild-type RT.
The deletion mutations were located throughout the lacZ␣ peptide gene region but in most instances had deletion junctions near locations that may be mutational hotspots. The deletion junctions for the simple deletions had either 3-or 1-bp homology (Fig. 3) . Interestingly, one simple deletion had no base-pair homology at the deletion junction. One deletion with an insertion mutant was also identified that did not have base pair homology at the deletion junctions. The observation that the simple deletions had fewer homologous base pairs at the deletion junctions suggests that M188A and M188V may be less processive than wild-type HTLV-1 RT.
Relative rate of mutation for HTLV-1 to that of BLV, HIV-1, and SNV using the lacZ␣ peptide gene region as a mutational target. The characterized mutants from replicating HTLV-1 with wild-type RT allowed for calculation of the in vivo mutation rate for HTLV-1. The mutation rate was calculated to be 7 ϫ 10 Ϫ6 mutation/target base pair/replication cycle (Table 3) . Target nucleotides in the mutational target have been previously described (1, 3, 36) . The mutant frequency for HTLV-1 is not significantly different ( 2 ϭ 1.2; P Ͼ 0.1) than that of BLV, but is fourfold lower than that of HIV-1 ( 2 ϭ 77; P Ͻ 0.001) and is twofold lower than the mutant frequency of SNV ( 2 ϭ 15; P Ͻ 0.005). This indicates that the HTLV-1 and BLV mutation rates are comparable, whereas the HTLV-1 mutation rate is significantly different from the HIV-1 and SNV mutation rates (Table 3) .
DISCUSSION
Determination of the HTLV-1 in vivo mutation rate. The accuracy of HTLV-1 reverse transcription has been determined. Using an HTLV-1 vector containing the lacZ␣ peptide gene region as a mutational target, the mutant frequency was determined to be 0.0009 mutant/replication cycle. Sequence analysis of the recovered mutants indicated substitution, frameshift, and deletion mutations had occurred. The predominant type of mutations to occur were G-to-A and C-to-T transition mutations. Deletion mutations were found to represent about one-quarter of the mutants recovered. The calculated in vivo mutation rate for HTLV-1, 7 ϫ 10 Ϫ6 mutation per target base pair per replication cycle, is comparable to that previously reported for BLV but is significantly different than that of HIV-1 and SNV.
Possible mechanisms responsible for the creation of mutations. The HTLV-1 vector used in these studies does not allow the determination of whether mutations occurred during minus-strand or plus-strand DNA synthesis, but the locations of the mutations suggest particular mechanisms for their creation. The majority of the G-to-A transitions characterized were in GpA dinucleotides. Transition mutations adjacent to runs of a single nucleotide appear to occur by the mechanism of dislocation mutagenesis (1, 22) . In this model, dislocation of the primer to the template produces an unpaired nucleotide base; realignment occurs between the primer and the template resulting in a mismatch, followed by elongation beyond the mismatch. Most of the G-to-A transition mutations occurred at sites adjacent to a run of nucleotides, which suggests that these mutations could have occurred by dislocation mutagenesis.
The frameshift mutations characterized were mainly ϩ1 frameshifts in runs of A's and T's. Plus-one frameshift mutations in runs of T's and A's occurred with SNV in vivo (4, 37) . The frameshift mutations in homo-oligomeric runs suggest 
Ϫ5
a Rates are in units of mutations/target base pair/replication cycle. The rates of mutation were calculated as the sums of the rates of base pair substitution, frameshift, and deletion mutations per number of independent vector proviruses recovered per 114 target nucleotides for substitutions, per 150 target nucleotides for frameshifts, or per 280 target nucleotides for deletion mutations. Target nucleotides have been previously described (1, 3, 36) .
b Data from Mansky and Temin (32) . c Combined data for HIV-1 mutation rate determined in HeLa cells and CEM-A cells (26, 31) . d Data from Pathak and Temin (37) .
that these result from template-primer slippage (2, 21, 46, 47) . The ϩ1 frameshift mutations may have occurred during minusstrand DNA synthesis (4), while the Ϫ1 frameshift mutations could have occurred during either minus-or plus-strand DNA synthesis. Simple deletion and deletion with insertion mutants have been previously identified and the mechanisms by which they could have occurred have been proposed (36, 40) . Mutation of M188 in HTLV-1 RT decreases reverse transcription accuracy. Two HTLV-1 RT variants, M188A and M188V, were found to significantly increase the rate of HTLV-1 mutation by a factor of 2 and therefore decrease the accuracy of HTLV-1 reverse transcription by twofold. The types of mutations that occurred during replication with these variants indicated a spectrum similar to what was observed with wild-type RT. However, limited number of mutants characterized suggests that the frequency of frameshift mutations doubled. Mutation of the YXDD motif may influence the template-primer affinity and could potentially influence frameshift fidelity.
Deletion rates. It has been observed that defective proviruses represent about 25 to 40% of all HTLV-1 genomes present in lymphocytes from infected individuals (many of which are defective due to deletion mutations in gag, pol, and/or env) (16, 19, 33, 49) . A large number of deleted HTLV-1 proviruses have also been observed in cell lines infected with a variety of HTLV-1 isolates (14) . These observations could indicate that these deletion mutations are created during the reverse transcription process at a higher rate than that observed for other retroviruses. However, comparison of the frequency of deletion mutations among retroviruses in which in vivo mutation rates have been determined using the lacZ␣ peptide gene as a mutational target does not support this (Table 3) . Rather, it indicates that HTLV-1 is no more prone to deletion mutations than BLV, HIV-1, or SNV.
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